Alexion Pharma Canada, a newly incorporated division of Alexion Pharmaceuticals, Inc., today announced the availability in Canada of Soliris(TM) (eculizumab) for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH), an ultra-rare, progressive and life-threatening blood disease characterized by chronic haemolysis, or red blood cell destruction.
The details can be read here.
No comments:
Post a Comment